13 completed, 4 terminated, 3 unknown, 2 recruiting. 25 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 13, Terminated 4, Unknown 3, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Suspended 1 |
| Phase 1 | 3 | Completed 2, Not yet recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Mitochondrial Myopathies: new trials by email Literature Review of Mitochondrial Myopathies trials Research Report on Mitochondrial Myopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM) zagociguat 15mg - Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome) | Phase 2 | Terminated | Tisento Therapeutics | 37 | 2025-08-18 | 2026-11-06 |
| A Study to Assess TTI-0102 vs Placebo in MELAS Patients TTI-0102, Placebo - MELAS Syndrome, Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS) | Phase 2 | Completed | Thiogenesis Therapeutics, Inc. | 9 | 2025-05-12 | 2026-07-24 |
| Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency Doxecitine and Doxribtimine - Thymidine Kinase 2 (TK2 ) Deficiency, Mitochondrial Myopathies | Phase 2 | Recruiting | Cristina Domínguez González | 15 | 2025-01-01 | 2026-09-17 |
| A Phase 2b Study of Zagociguat in Patients With MELAS zagociguat 15mg, zagociguat 30mg, Placebo - Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome) | Phase 2 | Completed | Tisento Therapeutics | 43 | 2024-09-10 | 2026-10-23 |
| Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD). Promoting Resilience in Stress Management (PRISM), Clinical-focused narrative (CFN) - Mitochondrial Diseases, Mitochondrial Myopathies | Phase 1 / Phase 2 | Completed | Children's Hospital of Philadelphia | 16 | 2023-09-22 | 2024-11-29 |
| Effect and Safety MABs Administration m.3243A>G Mutation Carriers Intra-arterial delivery of autologous MABs - Mitochondrial Myopathies | Phase 2 | Unknown | Maastricht University | 20 | 2023-08-01 | 2024-04-15 |
| A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy Nicotinamide Riboside, Placebo - Mitochondrial Myopathy | Phase 2 | Active not recruiting | Ralitza Gavrilova | 34 | 2023-05-26 | 2026-01-26 |
| OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION) OMT-28 - Primary Mitochondrial Disease | Phase 2 | Completed | Omeicos Therapeutics GmbH | 28 | 2023-05-22 | 2026-01-22 |
| Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome deoxycytidine and deoxythymidine - Mitochondrial Diseases, Mitochondrial Encephalomyopathy | Phase 2 | Recruiting | Kenneth Myers, MD | 200 | 2021-10-18 | 2026-10-19 |
| The KHENEREXT Study Oral administration of 100 mg KH176 twice daily - Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation | Phase 2 | Completed | Khondrion BV | 11 | 2021-08-09 | 2024-03-06 |
| The KHENERGYC Study Sonlicromanol, Placebo - Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation | Phase 2 | Suspended | Khondrion BV | 24 | 2021-02-01 | 2025-01-10 |
| Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) IW-6463 Tablets - MELAS | Phase 2 | Terminated | Tisento Therapeutics | 8 | 2020-11-13 | 2024-08-29 |
| A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 68 | 2020-09-28 | 2026-03-31 |
| The KHENERGYZE Study KH176, Placebo - Mitochondrial Diseases, Mitochondrial Myopathies | Phase 2 | Completed | Khondrion BV | 27 | 2019-10-30 | 2022-08-31 |
| The KHENERGY Study KH176, placebo - Mitochondrial Diseases, Mitochondrial Myopathies | Phase 2 | Completed | Khondrion BV | 20 | 2016-09-01 | 2018-02-23 |
| Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study Elamipretide, Placebo - Primary Mitochondrial Disease | Phase 2 | Completed | Stealth BioTherapeutics Inc. | 30 | 2016-08-22 | 2020-07-17 |
| A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease Cysteamine Bitartrate - Mitochondrial Diseases | Phase 2 | Terminated | Amgen | 22 | 2015-05-19 | 2024-12-27 |
| RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR Omaveloxolone capsules, 2.5 mg, omaveloxolone capsules, 5 mg, omaveloxolone capsules, 10 mg - MItochondrial Myopathies | Phase 2 | Completed | Biogen | 53 | 2015-05-05 | 2025-06-05 |
| Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy elamipretide (low dose), elamipretide (intermediate dose), elamipretide (high dose) - Mitochondrial Myopathy | Phase 1 / Phase 2 | Completed | Stealth BioTherapeutics Inc. | 36 | 2015-02-01 | 2019-12-27 |
Showing 20 of 25. Sign in to see all of them.
MELAS Syndrome (15) · Mitochondrial Diseases (11) · Acidosis, Lactic (6) · Mitochondrial Encephalomyopathies (6) · Mitochondrial encephalopathy (5) · Leigh Disease (4) · MERRF Syndrome (3) · Ophthalmoplegia, Chronic Progressive External (3) · Seizures (3) · Epilepsies, Myoclonic (2) · Muscular Diseases (2) · Noninsulin-dependent diabetes mellitus with deafness (2) · Optic Atrophy, Hereditary, Leber (2) · Anxiety Disorders (1)
Metabolic Diseases (25) · Musculoskeletal Diseases (25) · Nervous System Diseases (25) · Neuromuscular Diseases (25) · Nutritional and Metabolic Diseases (25) · Muscular Diseases (23) · Brain Diseases (18) · Brain Diseases, Metabolic (18) · Central Nervous System Diseases (18) · Brain Diseases, Metabolic, Inborn (17) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (17) · Genetic Diseases, Inborn (17) · Metabolism, Inborn Errors (17) · Cardiovascular Diseases (15) · Cerebral Small Vessel Diseases (15)
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (3) · Cysteamine (2) · arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide (2) · Arginine (1) · Bulk Drugs (1) · Deoxycytidine (1) · Dichloroacetic Acid (1) · Exercise (1) · ORF 50 transactivator (1) · Thymidine (1) · alpha-tocotrienol quinone (1) · cysteamine-pantetheine disulfide (1) · idebenone (1) · nicotinamide-beta-riboside (1) · omaveloxolone (1)
Khondrion BV (4) · Tisento Therapeutics (3) · Amgen (2) · Stealth BioTherapeutics Inc. (2) · Biogen (1) · Children's Hospital of Philadelphia (1) · Cristina Domínguez González (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · George Washington University (1) · Kenneth Myers, MD (1) · Maastricht University (1) · Michio Hirano (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · Omeicos Therapeutics GmbH (1) · PTC Therapeutics (1)
United States (15) · Netherlands (7) · Germany (5) · United Kingdom (5) · Canada (4) · Italy (4) · Denmark (3) · Australia (2) · France (2) · Spain (2) · Japan (1) · Poland (1) · Sweden (1)
Anne Chiaramello, Ph.D. (1) · Chad Glasser, PharmD (1) · Darryl C De Vivo, MD (1) · Debra Regier, M.D., Ph.D. (1) · Elizabeth M McCormick, MS (1) · Ingrid Tein, MD (1) · Janneke Hoeijmakers, MD, PhD (1) · Jim Carr (1) · Kenneth Alexis MD Myers, MD PhD FRCPC (1) · Lonneke de Boer, MD (1) · Michio Hirano, MD (1) · Patrice P Rioux, MD, PhD (1) · Ralitza H. Gavrilova, MD (1)
PMID 11182283, PMID 12013896, PMID 12508073, PMID 12771225, PMID 12826641, PMID 15090651, PMID 15684706, PMID 16621917, PMID 16971696, PMID 16971699, PMID 17080429, PMID 17353390, PMID 17483096, PMID 17486094, PMID 17549623, PMID 18238797, PMID 18467430, PMID 18546365, PMID 19103785, PMID 19125351, PMID 19138848, PMID 19192035, PMID 19667227, PMID 19766516, PMID 19889013, PMID 20301762, PMID 20301791, PMID 20329599, PMID 20444604, PMID 21483760, PMID 21774628, PMID 21855607, PMID 22084276, PMID 22176657, PMID 22608879, PMID 22711161, PMID 23168274, PMID 23169334, PMID 23230576, PMID 23385875, PMID 23714749, PMID 23817075, PMID 245993, PMID 24708634, PMID 24985751, PMID 25857492, PMID 25993630, PMID 26342080, PMID 26760297, PMID 27554452
R01AR050597 (1), U54NS078059 (1), UH3TR003897 (1)